The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function

Aims This open label study was conducted to assess the effect of renal impairment (RI) on the pharmacokinetics (PK) of peginterferon lambda‐1a (Lambda). Methods Subjects (age 18–75 years, BMI 18–35 kg m –2 ) were enrolled into one of five renal function groups: normal ( n = 12), mild RI ( n = 8), moderate RI ( n = 8), severe RI ( n = 7), end‐stage renal disease (ESRD, n = 8) based on estimated glomerular filtration rate (eGFR) calculated using...